Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 164   

Articles published

BMY 72.01 +1.69 (2.40%)
price chart
Bristol-Myers Squibb Co (NYSE:BMY)Analyst Research Summary:
Bristol-Myers Squibb Co (NYSE:BMY)stock is currently trading at about $70.32 and lots of rating firms seem to have a target price set on the stock.
Bristol-Myers Squibb Co Wins a Sixth Breakthrough Tag for Opdivo  Bidness ETC
Bristol-Myers Squibb Co (BMY) Bucks Market Sell-Off on Upbeat Drug News  Schaeffers Research (blog)
Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy ...
Bristol-Myers Squibb Co. BMY, -0.41% said Monday that its bladder cancer treatment, Opdivo, was granted breakthrough therapy designation by the Food and Drug Administration.
GW Pharmaceuticals (NASDAQ:GWPH) & Bristol-Myers Squibb Co (NYSE:BMY ...
On Monday, Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) gained 6.22% to $88.49. The share price is trading in a range of $83.32 - $93.70.
GW Pharmaceuticals Stock Up on Positive Epidiolex Data  Zacks.com
Is Bristol-Myers Squibb Co (NYSE:BMY) an Incredibly Valuable Stock?
[Capital Cube] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) has a fundamental score of 59 and has a relative valuation of OVERVALUED.
Analysts Advise About Bristol-Myers Squibb Co (NYSE:BMY)  Zergwatch
Two Movers inside Analysts Radar: Bristol-Myers Squibb Company (NYSE:BMY ...  Street Updates
Here's Why Leerink Partners Is More Positive On Bristol-Myers Squibb Co (BMY ...
Leerink Partners LLC analyst, Seamus Fernandez sharpened his pencils on Keytruda after Merck & Co., Inc. (NYSE:MRK) announced that patients who received Keytruda fared better compared to those who received chemotherapy.
Could Merck Beat Bristol-Myers To Market?  Seeking Alpha
Bristol-Myers Squibb Co (NYSE:BMY) Analysts Recommendations and Insider Trading
Bristol-Myers Squibb Co (NYSE:BMY)stock is currently trading at about $72.57 and lots of rating firms seem to have a target price set on the stock.
Is an Investment in Bristol-Myers Squibb Co (NYSE:BMY) as Risky as Its ...  Street Report
Analyst Activity: Bristol-Myers Squibb Co (NYSE:BMY)  CWRU Observer
Bristol-Myers Squibb Co (NYSE:BMY) Analyst Estimates
Bristol-Myers Squibb Co (NYSE:BMY)stock is currently trading at about $72.89 and lots of rating firms seem to have a target price set on the stock.
Analysts Insights on Bristol-Myers Squibb Co (NYSE:BMY)  The Point Review
Bristol-Myers Squibb Company (BMY) Is Today's Momo Momentum Stock  TheStreet.com
BRIEF-Bristol-Myers Squibb's Opdivo gets breakthrough therapy approval from FDA
June 27 Bristol Myers Squibb Co. * Bristol Myers Squibb Co - intends to file marketing application with health authorities based on results from phase 2 study ca209-275, other data.
Read the Analyst's Study: Pfizer, Inc. (NYSE:PFE) , Bristol-Myers Squibb ...
Pfizer, Inc. (NYSE:PFE) negotiated 44 million shares against it an average volume of 37.83 million shares. The stock concluded the recent trade at $33.97 with downbeat trend move of -1.79%.
News Sentiment For Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) has been given a sentiment score of 0.199 by research firm. Coming to the sentiment scale, the impact score measured on daily basis stands on a 1-100 scale.